Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

被引:1445
作者
Brown, BG
Zhao, XQ
Chait, A
Fisher, LD
Cheung, MC
Morse, JS
Dowdy, AA
Marino, EK
Bolson, EL
Alaupovic, P
Frohlich, J
Albers, JJ
Serafini, L
Huss-Frechette, E
Wang, S
DeAngelis, D
Dodek, A
机构
[1] Univ Washington, Sch Med, Dept Med, Div Cardiol, Seattle, WA 98195 USA
[2] Univ Washington, Sch Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA
[3] Univ Washington, Sch Med, Dept Biostat, Seattle, WA 98195 USA
[4] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA
[5] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada
关键词
D O I
10.1056/NEJMoa011090
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Both lipid-modifying therapy and antioxidant vitamins are thought to have benefit in patients with coronary disease. We studied simvastatin-niacin and antioxidant-vitamin therapy, alone and together, for cardiovascular protection in patients with coronary disease and low plasma levels of high-density lipoprotein (HDL) cholesterol. Methods: In a three-year, double-blind trial, 160 patients with coronary disease, low HDL cholesterol levels, and normal low-density lipoprotein (LDL) cholesterol levels were randomly assigned to receive one of four regimens: simvastatin plus niacin, antioxidants, simvastatin-niacin plus antioxidants, or placebos. The end points were arteriographic evidence of a change in coronary stenosis and the occurrence of a first cardiovascular event (death, myocardial infarction, stroke, or revascularization). Results: The mean levels of LDL and HDL cholesterol were unaltered in the antioxidant group and the placebo group; these levels changed substantially (by -42 percent and +26 percent, respectively) in the simvastatin-niacin group. The protective increase in HDL2 with simvastatin plus niacin was attenuated by concurrent therapy with antioxidants. The average stenosis progressed by 3.9 percent with placebos, 1.8 percent with antioxidants (P=0.16 for the comparison with the placebo group), and 0.7 percent with simvastatin-niacin plus antioxidants (P=0.004) and regressed by 0.4 percent with simvastatin-niacin alone (P<0.001). The frequency of the clinical end point was 24 percent with placebos, 3 percent with simvastatin-niacin alone, 21 percent in the antioxidant-therapy group, and 14 percent in the group given simvastatin-niacin plus antioxidants. Conclusions: Simvastatin plus niacin provides marked clinical and angiographically measurable benefits in patients with coronary disease and low HDL levels. The use of antioxidant vitamins in this setting must be questioned. (N Engl J Med 2001;345:1583-92.) Copyright (C) 2001 Massachusetts Medical Society.
引用
收藏
页码:1583 / 1592
页数:10
相关论文
共 39 条
  • [1] Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
  • [2] [Anonymous], LANCET
  • [3] Assmann G, 1998, EUR HEART J, V19, pA2
  • [4] BROWN BG, 1993, CIRCULATION, V87, P66
  • [5] BROWN BG, 1986, PROG CARDIOVASC DIS, V28, P403
  • [6] Brown BG, 1998, CAN J CARDIOL, V14, p6A
  • [7] REGRESSION OF CORONARY-ARTERY DISEASE AS A RESULT OF INTENSIVE LIPID-LOWERING THERAPY IN MEN WITH HIGH-LEVELS OF APOLIPOPROTEIN-B
    BROWN, G
    ALBERS, JJ
    FISHER, LD
    SCHAEFER, SM
    LIN, JT
    KAPLAN, C
    ZHAO, XQ
    BISSON, BD
    FITZPATRICK, VF
    DODGE, HT
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (19) : 1289 - 1298
  • [8] BRUCE RA, 1971, ANN CLIN RES, V3, P323
  • [9] CHEUNG MC, 1991, J LIPID RES, V32, P383
  • [10] Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL
    Cheung, MC
    Zhao, XQ
    Chait, A
    Albers, JJ
    Brown, BG
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (08) : 1320 - 1326